Benitec Biopharma (BNTC) to Release Earnings on Thursday

Key Points

• Benitec Biopharma is set to announce its Q4 2025 earnings on September 25th, with analysts predicting a loss of ($0.24) per share.
• The company has experienced significant changes in ownership, with hedge funds now holding 52.19% of its stock, indicating growing institutional interest.
• Analysts have generally given a positive outlook, with a consensus rating of "Buy" and a target price of $24.80 for Benitec Biopharma shares.

Benitec Biopharma (NASDAQ:BNTC - Get Free Report) is expected to be posting its Q4 2025 results before the market opens on Thursday, September 25th. Analysts expect Benitec Biopharma to post earnings of ($0.24) per share for the quarter. Individuals may visit the the company's upcoming Q4 2025 earningresults page for the latest details on the call scheduled for Thursday, October 2, 2025 at 4:00 PM ET.

Benitec Biopharma Trading Down 3.9%

Shares of Benitec Biopharma stock traded down $0.54 during trading hours on Friday, hitting $13.45. The company's stock had a trading volume of 174,584 shares, compared to its average volume of 44,115. The firm has a fifty day moving average of $12.58 and a 200-day moving average of $13.46. Benitec Biopharma has a twelve month low of $8.20 and a twelve month high of $17.15. The company has a debt-to-equity ratio of 0.01, a quick ratio of 14.80 and a current ratio of 14.80. The stock has a market cap of $353.06 million, a price-to-earnings ratio of -8.91 and a beta of 0.43.

Wall Street Analysts Forecast Growth

Several brokerages have weighed in on BNTC. TD Cowen began coverage on Benitec Biopharma in a report on Monday, July 7th. They set a "buy" rating on the stock. Oppenheimer reissued an "outperform" rating and issued a $29.00 price target (down from $35.00) on shares of Benitec Biopharma in a report on Tuesday, September 16th. One investment analyst has rated the stock with a Strong Buy rating and seven have issued a Buy rating to the company. According to MarketBeat, Benitec Biopharma currently has a consensus rating of "Buy" and a consensus price target of $24.80.

Hedge Funds Weigh In On Benitec Biopharma

Hedge funds have recently bought and sold shares of the stock. Bank of America Corp DE boosted its holdings in Benitec Biopharma by 2,255.8% in the second quarter. Bank of America Corp DE now owns 6,879 shares of the biotechnology company's stock valued at $80,000 after acquiring an additional 6,587 shares during the last quarter. Ameriprise Financial Inc. increased its holdings in Benitec Biopharma by 219.4% in the second quarter. Ameriprise Financial Inc. now owns 109,925 shares of the biotechnology company's stock valued at $1,286,000 after buying an additional 75,507 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. bought a new stake in Benitec Biopharma in the second quarter valued at about $93,000. Marshall Wace LLP bought a new stake in Benitec Biopharma in the second quarter valued at about $503,000. Finally, New York State Common Retirement Fund bought a new position in shares of Benitec Biopharma during the second quarter valued at approximately $95,000. Hedge funds and other institutional investors own 52.19% of the company's stock.

Benitec Biopharma Company Profile

Benitec Biopharma Inc, a clinical-stage biotechnology company, focuses on the development of novel genetic medicines. The company develops DNA-directed RNA interference-based therapeutics for chronic and life-threatening human conditions. It is developing BB-301, an adeno-associated virus based gene therapy agent for treating oculopharyngeal muscular dystrophy.